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Abstract
Background: Lower respiratory tract infections due to Pseudomonas aeruginosa have a high
mortality rate. Antibacterial activity of various antibiotics against P. aeruginosa isolated from each
hospital depends on the variety or amount of antibiotics used in each hospital.
Method: A total of 249 respiratory isolates of Pseudomonas aeruginosa in Sivas (Turkey) were
included between January-1999 and January-2002. Isolates were tested against 14 different
antibiotics by a disc diffusion method or standardized microdilution technique.
Results: Organisms were cultured from the following specimens: sputum (31.3%), transtracheal/
endotracheal aspirates (37.8%), and bronchial lavage (30.9%). Isolates in bronchial lavage were
highly susceptible to cefoperazone and aminoglycosides. Resistance to ampicillin/sulbactam was
98.8%, ticarcillin 40.1%, ticarcillin/clavulanic acid 11.2%, piperacillin 21.8%, aztreonam 66.6%,
cefotaxim 75.4%, ceftriaxone 84.2%, cefoperazone 39.0%, ceftazidime 50.8%, gentamicin 57.5%,
tobramycin 58.4%, amikacin 25.4%, ciprofloxacin 16.1%, and imipenem/cilastatin 21.6%. The term
multidrug-resistant P. aeruginosa covered resistance to imipenem, ciprofloxacin, ceftazidime,
gentamicin, and piperacillin. 1.2% of isolates were multidrug-resistant.
Conclusions: These findings suggest that amikacin resistance increases progressively in Turkey.
Piperacillin and ticarcillin/clavulanate were the most active agents against both imipenem- and
ciprofloxacin-resistant isolates in our region.
Background
Pseudomonas aeruginosa is primarily a nosocomial patho-
gen and the most common gram-negative bacillus causing
hospital-acquired pneumonia. Despite therapy, the mor-
tality from hospital-acquired pseudomonal pneumonia is
approximately 70 percent [1]. Unfortunately, there are no
specific measures to prevent nosocomial pseudomonal
infections. Despite the availability of a variety of effective
antimicrobial agents, treatment of pseudomonal pneu-
monia is often challenging. The aim of this study was to
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reveal the antibiotic susceptibility patterns of Pseu-
domonas aeruginosa isolated airway samples in Sivas,
Central Anatolia.
Material and methods
The antibiotic susceptibility patterns of 249 respiratory
isolates of Pseudomonas aeruginosa were retrospectively
analyzed. Data between 01.01.1999 and 01.01.2002 was
obtained in microbiology laboratory of University of
Cumhuriyet and processed to eliminate duplicate registra-
tions. The isolates were identified conventional or autom-
atized (Api) techniques. Isolates collected from the same
specimen source of the same patient within 7 days were
excluded. Organisms were cultured from the following
specimens: sputum (31.3%), transtracheal/endotracheal
aspirates (37.8%), and bronchial lavage (30.9%). All con-
secutive isolates were accepted, as we did not attempt to
distinguish the actual pathogens from colonizing strains.
Susceptibility to 14 antimicrobial agents was confirmed at
the central laboratory by disk diffusion according to the
National Committee for Clinical Laboratory Standards
guidelines [2]. Inoculated plates were incubated aerobi-
cally at 35°C and estimated after 18 h. For quality control
of the disk diffusion tests E. coli ATCC 25922 and S. au-
reus ATCC 25923 strains were used. Disk diffusion meth-
od was used until November 1999 in our microbiology
laboratory, and later antibiotic resistance patterns were
analyzed by a co-ordinating laboratory that determined
minimal inhibitory concentrations of these 14 antimicro-
bial agents using a standardized microdilution technique
(Sceptor system, Becton Dickinson Microbiology System).
The results of the susceptibility testing were classified into
two categories. The category "susceptible" was defined as
identification of a strain as susceptible by the disk diffu-
sion method or microdilution technique. All resistant and
intermediate isolates of the species were classified under
the definition "resistant".
The significance of differences in resistance was evaluated
using EpiInfo software (version 5.0). Susceptibility and re-
sistance were calculated as percentages with 95% confi-
dence intervals. The X2  test with Yates correction or
Fisher's exact two-tailed test was used to assess the associ-
ation of selected variables with the prevalence of resistant
isolates. The analysis was performed on the cross-tabulat-
ed values of the presence of the resistant/susceptible iso-
lates, according to the categories of the selected variable.
A p-value of <0.05 was considered statistically significant.
Results
The antibiotic resistance patterns of isolates are presented
in Table 1. Compared to those in sputum or tracheal aspi-
rates, isolates in bronchial lavage were more susceptible to
ticarcillin, aztreonam, cefoperazone, ceftriaxone, ceftazi-
dime, gentamicin, tobramycin, amikacin (p < 0.01), and
cefotaxim (p < 0.05). Isolates in tracheal aspirates were
more resistant to ceftriaxone (p < 0.01), gentamicin (p <
0.01), tobramycin (p < 0.05), and amikacin (p < 0.05)
than in sputum.
The term multidrug-resistant P. aeruginosa covered resist-
ance to imipenem, ciprofloxacin, ceftazidime, gen-
tamicin, and piperacillin. Among the 249 isolates, 3
(1.2%) were designated as being multidrug-resistant.
Table 1: Resistance rates (percentages) of Pseudomonas aeruginosa to antibiotics
Site of isolation
Antibiotic MIC 50/90 Sputum n = 78 Tracheal aspirates n = 94 Bronchial lavage n = 77
Ampicillin/sulbactam 8/32 96.6 100 100
Ticarcillin 16/128 50.0 55.2 15.2
Ticarcillin/clavulanic 
acid
16/>64 7.3 15.1 15.0
Piperacillin 16/128 22.7 20.9 21.6
Aztreonam 2/>16 70.0 79.1 49.2
Cefotaxim 8/>32 76.1 89.5 60.0
Ceftriaxone 16/64 86.9 100 66.1
Cefoperazone 16/64 56.4 55.5 4.2
Ceftazidime 1/>16 54.0 67.4 27.6
Gentamicin 4/>8 68.8 86.0 11.7
Tobramycin 4/>8 63.1 79.3 29.3
Amikacin 16/64 25.3 40.9 6.6
Ciprofloxacin 1/4 16.6 18.1 13.1
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The antibiotic resistance patterns of imipenem-, gen-
tamicin-, and ciprofloxacin-resistant isolates are presented
in Table 2. Compared to the entire group, ciprofloxacin-
resistant strains were more resistant to five classes of anti-
pseudomonal agents (aminoglycosides, extended-spec-
trum cephalosporins, carboxypenicillins, monobactam,
and carbapenem), whereas gentamicin-resistant strains
(aminoglycosides, extended-spectrum cephalosporins,
carboxypenicillins, monobactam) and imipenem-resist-
ant strains (aminoglycosides, extended-spectrum cepha-
losporins, carboxypenicillins, quinolones) more resistant
to four classes of anti-pseudomonal agents (p < 0.05). Im-
ipenem-resistant strains were more susceptible to aztreon-
am than ciprofloxacin-resistant strains, and to tobramycin
than gentamicin-resistant strains (p < 0.05). Piperacillin
and ticarcillin/clavulanate were the most active agents
against both imipenem- and ciprofloxacin-resistant
strains.
There was not significant difference in the susceptibility to
ureidopenicillins in imipenem-, gentamicin-, and cipro-
floxacin-resistant strains compared to the entire group.
Piperacillin-resistant strains were more resistant to aztre-
onam, ceftazidime, ticarcillin, and ticarcillin/clavulanate
than the entire group. Piperacillin-resistant strains were
more susceptible to cefotaxim and tobramycin but, more
resistant to ticarcillin/clavulanate than gentamicin-resist-
ant strains (p < 0.05).
Discussion
Resistance of gram-negative aerobic bacteria to aminogly-
coside antibiotics differs by region and country. Resist-
ance to aminoglycosides was higher in Southern Europe
than in Central and Northern Europe. Reports of the sus-
ceptibility of P. aeruginosa to gentamicin and tobramycin
have ranged from as low as 49.8% and 77.7%, in Greece,
to as high as 96.6% and 99.2%, respectively, in the United
Kingdom [3]. It was reported that 54% of gram-negative
bacilli in Turkey are resistant to gentamicin, 35% to to-
bramycin, and only 0.9% to amikacin in 1988 [4]. Con-
sistent to this finding, resistance to amikacin (25.4%) of
P. aeruginosa was still lower than to gentamicin (57.5%)
or tobramycin (58.4%). However, this data suggests that
resistance to amikacin increases progressively in Turkey.
Isolates in tracheal aspirates were highly resistant whereas
isolates obtained from bronchial lavage fluids were rela-
tively quite susceptible. In our hospital, tracheal aspira-
tion is generally a procedure performed in intensive care
units or the patients with critical illness. Consequently,
our isolates in tracheal aspirates may reflect nosocomial
strains. On the other hand, bronchoscopy, a lesser inva-
sive procedure, was generally performed to newly hospi-
talised patients. The variations of antibiotic resistance for
different locations may be due to the isolation
procedures.
Resistance to imipenem was 14% in Spain [5], 19.3% in
Italy [6], and 68% in Saudi Arabia [7]. Our result is similar
to Latin America (SENTRY Antimicrobial Surveillance
Program, 1998), 21.6% and 21%, respectively [8].
Resistance to ciprofloxacin of our isolates was 16.1%,
whereas this rate 23% in Spain [5], 31.9% in Italy [6], and
26.8% in Latin America [8]. Contrary to ciprofloxacin, our
isolates were highly resistant to ceftazidime (50.8%). Re-
sistance to ceftazidime was 15% [5], 13.4% [6], and 22%
[8] in other site of the World. Resistance to piperacillin
was higher like ceftazidime. This rate was 10% in Spain,
12% in Italy, 14% in Latin America, 21.8% in our study.
Resistance rates of anti-pseudomonal antibiotics were
Table 2: Resistance rates (percentages) of imipenem-, gentamicin-, piperacillin-, and ciprofloxacin-resistant isolates
Antibiotic All isolates
n = 249
Imipenem-resistant
n = 49
Gentamicin-resistant
n = 137
Ciprofloxacin-resistant
n = 40
Piperacillin-resistant
n = 43
Aztreonam 66.6 79.4 89.7 100 83.3
Cefoperazone 39.0 68.0 68.4 72.7 57.7
Cefotaxim 75.4 90.9 94.7 96.1 82.1
Ceftazidime 50.8 77.0 73.5 79.5 76.9
Ceftriaxone 84.2 93.7 95.3 93.5 89.7
Ciprofloxacin 16.1 32.6 21.1 100 18.6
Imipenem 21.6 100 29.9 45.5 21.4
Tobramycin 58.4 74.5 88.5 78.9 69.0
Amikacin 25.4 49.0 41.2 28.9 30.2
Gentamicin 57.5 77.5 100 75.0 64.3
Piperacillin 21.8 20.6 27.9 27.6 100
Ticarcillin 40.1 74.0 67.1 66.7 68.2
Ticarcillin/clavulanic 
acid
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quite low in United Kingdom: 5% for ceftazidime, 7% for
piperacillin, 10% for ciprofloxacin, and 11% for imipen-
em [9].
Isolates that were resistant to one class of antibiotics were
also resistant to at least one other class of antibiotics ex-
cept resistance to piperacillin. This finding suggests that
piperacillin resistance occur independently and specifical-
ly in our isolates compared to other anti-pseudomonal
agents. One hundred isolates were resistant to ticarcilin
but 81 of them were susceptible to ticarcillin-clavulanate,
which suggests that the production of β-lactamase may be
the major mechanism of resistance in these organisms.
Gaynes and Culver demonstrated that resistance was more
common among P. aeruginosa isolated from the respira-
tory tract, patients in intensive care units, and in teaching
hospitals [10]. In spite of this knowledge, it was found
only three multidrug-resistant isolates in 3-year survey.
We think that our rate of multidrug-resistance (1.2%) was
reasonable.
Conclusions
Because of high resistance rates to extended-spectrum ce-
phalosporins and the progression of amikacin resistance,
a national strategy on the limited and prudent use of anti-
pseudomonal agents is urgently needed in Turkey.
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